Valbenazine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Journal: The Journal of clinical psychiatry

Published: May 07, 2026

Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report.

Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report.

Journal: Neuropsychopharmacology reports

Published: January 31, 2026

VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.

VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.

Journal: CNS spectrums

Published: October 22, 2025

Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.

Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.

Journal: PCN reports : psychiatry and clinical neurosciences

Published: October 11, 2025

Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review.

Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review.

Journal: Parkinsonism & related disorders

Published: September 26, 2025

Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD).

Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD).

Journal: Cureus

Published: September 19, 2025

Acute exacerbation of major depressive disorder following valbenazine treatment for tardive dyskinesia: A case report.

Acute exacerbation of major depressive disorder following valbenazine treatment for tardive dyskinesia: A case report.

Journal: PCN reports : psychiatry and clinical neurosciences

Published: August 14, 2025

Consultation-Liaison Case Conference: Stimulant-Induced Tardive Dyskinesia.

Consultation-Liaison Case Conference: Stimulant-Induced Tardive Dyskinesia.

Journal: Journal of the Academy of Consultation-Liaison Psychiatry

Published: August 13, 2025

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Journal: Medical sciences (Basel, Switzerland)

Published: August 01, 2025

Huntington Disease and Chorea.

Huntington Disease and Chorea.

Journal: Continuum (Minneapolis, Minn.)

Published: August 01, 2025

The role of the vesicular monoamine transporter 2 in the inhibitory effect of tetrabenazine and valbenazine compared to reserpine on the vesicular release of monoamine transmitters.

The role of the vesicular monoamine transporter 2 in the inhibitory effect of tetrabenazine and valbenazine compared to reserpine on the vesicular release of monoamine transmitters.

Journal: Frontiers in cellular neuroscience

Published: June 19, 2025

Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.

Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.

Journal: Clinical and translational science

Published: June 10, 2025

Showing 1-12 of 182

Last Updated: 06/30/2026